The Federal Dupixent Litigation Has Entered a New Phase On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation (JPML) centralized federal lawsuits alleging that Dupixent (dupilumab) caused, accelerated, or delayed the diagnosis of cutaneous T-cell...
Mass tort developments move quickly. A new multidistrict litigation filing, centralization order, expert ruling, bellwether result, regulatory communication, or reported settlement development can create immediate pressure inside a plaintiff firm: Should we launch a...
Social media addiction litigation creates an unusual tension for plaintiff law firms: some of the companies named as defendants also operate the advertising and content-distribution platforms firms use to reach potential claimants. Meta, TikTok,...
GLP-1 medications have become one of the most visible drug categories in the country, and the public conversation around side effects has grown just as quickly. Patients are posting about nausea, vomiting, constipation, gallbladder issues, delayed gastric emptying,...
Mass tort marketing often moves fast. When a new litigation opportunity gains momentum, plaintiff firms need timely visibility, clear messaging, and intake pathways that can convert qualified claimants before competitors dominate the conversation. But...
Social media harm litigation is moving from a novel theory to a serious plaintiff-side practice area. The legal theory is no longer limited to harmful posts or third-party content. Increasingly, plaintiffs are focusing on platform design itself: recommendation...
